# A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma

> **NCT04195958** · PHASE4 · TERMINATED · sponsor: **Genentech, Inc.** · enrollment: 3 (actual)

## Conditions studied

- Moderate-to-severe Allergic Asthma

## Interventions

- **DRUG:** Omalizumab

## Key facts

- **NCT ID:** NCT04195958
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-11-30
- **Primary completion:** 2021-10-18
- **Final completion:** 2021-10-18
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Due to low enrollment, this study was terminated early.
- **Last updated:** 2022-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04195958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04195958, "A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04195958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*